行情

BPTH

BPTH

Bio-Path控股
NASDAQ

实时行情|Nasdaq Last Sale

12.30
+0.11
+0.90%
已收盘, 18:51 10/22 EDT
开盘
12.02
昨收
12.19
最高
12.86
最低
12.02
成交量
5.92万
成交额
--
52周最高
73.52
52周最低
1.610
市值
3,547.05万
市盈率(TTM)
-1.2379
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

BPTH 新闻

  • Houston biotech co. avoids stock exchange delisting amid board shakeup
  • American City Business Journals.6天前
  • Bio-Path Holdings Appoints Martina Molsbergen to Board of Directors
  • GlobeNewswire.10/15 13:00
  • 64 Biggest Movers From Yesterday
  • Benzinga.10/15 09:07
  • Microcaps mostly among midday movers
  • Seeking Alpha - Article.10/14 16:45

更多

所属板块

生物技术和医学研究
+0.44%
制药与医学研究
+0.60%

热门股票

名称
价格
涨跌幅

BPTH 简况

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer.
展开

Webull提供Bio-Path Holdings Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。